for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

22UAy.F

Latest Trade

90.00EUR

Change

2.00(+2.27%)

Volume

35,076

Today's Range

84.20

 - 

91.39

52 Week Range

25.51

 - 

109.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Pfizer And Biontech Reach Agreement With Covax

Jan 22 (Reuters) - BIONTECH SE <22UAy.DE>::PFIZER AND BIONTECH REACH AGREEMENT WITH COVAX FOR ADVANCE PURCHASE OF VACCINE TO HELP COMBAT COVID-19.DOSES WILL BE DELIVERED THROUGHOUT 2021.INITIAL AGREEMENT PROVIDES UP TO 40 MILLION DOSES TO COVAX IN 2021.FIRST DELIVERIES ARE EXPECTED TO TAKE PLACE IN Q1 2021 SUBJECT TO EXECUTION OF SUPPLY AGREEMENTS UNDER COVAX FACILITY STRUCTURE.

Pfizer And Biontech Publish Results Of Study

Jan 20 (Reuters) - BIONTECH SE <22UAy.DE>::PFIZER AND BIONTECH PUBLISH RESULTS OF STUDY SHOWING COVID-19 VACCINE ELICITS ANTIBODIES THAT NEUTRALIZE PSEUDOVIRUS BEARING THE SARS-COV-2 U.K. STRAIN SPIKE PROTEIN IN CELL CULTURE.

Canada says Pfizer to slow deliveries of COVID-19 vaccines - procurement minister

Jan 15 (Reuters) - Canada's Procurement Minister Anita Anand says::PFIZER WILL TEMPORARILY SLOW DELIVERIES OF VACCINE DUE TO PRODUCTION PROBLEMS FOR ALL COUNTRIES SUPPLIED BY ITS EUROPEAN FACTORY .CANADA STILL WILL BE ABLE TO REACH GOAL TO OFFER VACCINATIONS TO ALL CANADIANS BY END OF SEPT .PFIZER PRODUCTION DELAY IS DUE TO WORK EXPANDING MANUFACTURING CAPACITY AND IS TO BE EXPECTED WHEN GLOBAL SUPPLY CHAINS ARE STRETCHED WELL BEYOND LIMITS . (Reporting by Steve Scherer). ((Steve.Scherer@thomsonreuters.com;)).

EMA Says To Evaluate Safety Reports Of COVID-19 Vaccines From January

Jan 15 (Reuters) - European Medicines Agency (EMA): :STARTING THIS MONTH, EMA’S SAFETY COMMITTEE (PRAC) TO EVALUATE SAFETY REPORTS SUBMITTED BY MARKETING AUTHORISATIONS HOLDERS OF COVID-19 VACCINES.PFIZER IS EXPECTED TO SUBMIT THEIR MONTHLY SUMMARY SAFETY REPORT IN MID-JANUARY.FIRST SUCH REPORT WILL BE FOR COMIRNATY.MONTHLY SUMMARY SAFETY REPORT WILL INCLUDE INFORMATION ON REPORTED SUSPECTED ADVERSE REACTIONS, INCLUDING ADVERSE EVENTS OF SPECIAL INTEREST.

BioNTech Releases Statement On Voluntary Covid-19 Vaccination For BioNTech Employees, Suppliers

Jan 11 (Reuters) - BioNTech SE <22UAy.DE>::STATEMENT ON VOLUNTARY COVID-19 VACCINATION FOR BIONTECH EMPLOYEES, SUPPLIERS TO ENSURE UNDISRUPTED MANUFACTURING, DISTRIBUTION OF COVID-19 VACCINE DOSES.BIONTECH SE - DECIDED TO OFFER A VOLUNTARY COVID-19 VACCINATION TO ITS EMPLOYEES IN GERMANY.BIONTECH - WILL MAKE VACCINE AVAILABLE TO SUPPLIERS, DISTRIBUTION PARTNERS IN GERMANY, AUSTRIA WHO ARE INVOLVED IN PRODUCTION, DISTRIBUTION PROCESS.BIONTECH - PARTICIPATION IN EMPLOYEE VACCINATION PROGRAM IS ENTIRELY VOLUNTARY.BIONTECH - ALL COSTS ASSOCIATED WITH EMPLOYEE VACCINATION PROGRAM WILL BE COVERED BY BIONTECH.BIONTECH - EMPLOYEES, SUPPLIERS VACCINATION PROGRAM WILL NOT IMPACT ABILITY TO MEET COMMITMENTS UNDER SUPPLY AGREEMENTS.

Biontech SE says In Talks With EC About Amendment To Existing Supply Agreement For Comirnaty

Jan 8 (Reuters) - BioNTech SE <22UAy.DE>::BIONTECH SE - IN TALKS WITH EC ABOUT AMENDMENT TO EXISTING SUPPLY AGREEMENT FOR COMIRNATY, THE PFIZER-BIONTECH COVID-19 VACCINE.BIONTECH SE - ADDITIONAL DOSES OF PFIZER-BIONTECH COVID-19 VACCINE WOULD BE DELIVERED TO EU STARTING IN Q2 OF 2021.

EMA Says CHMP Recommends Updating Product Information For Pfizer's Comirnaty Vaccine

Jan 8 (Reuters) - EMA::EMA SAYS EXTRA DOSE FROM VIALS OF COMIRNATY COVID-19 VACCINE.EMA- EMA'S HUMAN MEDICINES COMMITTEE (CHMP) RECOMMENDED UPDATING PRODUCT INFORMATION FOR COMIRNATY TO CLARIFY THAT EACH VIAL CONTAINS 6 DOSES OF VACCINE.EMA - IF AMOUNT OF PFIZER VACCINE REMAINING IN VIAL AFTER 5TH DOSE CANNOT PROVIDE FULL DOSE (0.3 ML), HEALTHCARE PROFESSIONAL MUST DISCARD VIAL, ITS CONTENTS.EMA - THERE SHOULD BE NO POOLING FROM MULTIPLE VIALS TO MAKE UP A FULL DOSE, AND ANY UNUSED VACCINE SHOULD BE DISCARDED 6 HOURS AFTER DILUTION.

Pfizer Says In Talks With EU Over Addl Vaccine Supplies

Jan 8 (Reuters) - Pfizer Inc <PFE.N>::PFIZER SAYS WE ARE IN TALKS WITH EUROPEAN COMMISSION ABOUT AMENDMENT TO EXISTING SUPPLY AGREEMENT FOR PFIZER-BIONTECH COVID-19 VACCINE COMIRNATY.PFIZER SAYS IN TALKS WITH EU OVER FIRM ORDER FOR ADDITIONAL 200 MILLION DOSES OF COMIRNATY TO BE SUPPLIED TO 27 EU MEMBER STATES, WITH OPTION FOR ADDITIONAL 100 MILLION DOSES.PFIZER SAYS AMENDMENT WOULD ADD TO 300 MILLION DOSES ALREADY COMMITTED TO EU FOR 2021.PFIZER SAYS THIS WOULD BRING TOTAL DELIVERY OF DOSES TO EU MEMBER STATES BY END-2021 TO 500 MILLION, PLUS 100 MILLION DOSES IF EU EXERCISES OPTION.Further company coverage: PFE.N. ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).

WHO Says Pfizer/BioNTech COVID-19 Vaccine Today Became First Vaccine To Receive WHO Validation For Emergency Use - Tweet

Dec 31 (Reuters) - :WHO SAYS PFIZER/BIONTECH COVID-19 VACCINE TODAY BECAME FIRST VACCINE TO RECEIVE WHO VALIDATION FOR EMERGENCY USE - TWEET.

Pfizer And Biontech Receive Conditional Marketing Authorization By Swissmedic For COVID-19 Vaccine

Dec 19 (Reuters) - Pfizer Inc <PFE.N>::PFIZER AND BIONTECH RECEIVE CONDITIONAL MARKETING AUTHORIZATION BY SWISSMEDIC FOR COVID-19 VACCINE.DELIVERIES WILL START IN 2020 AND WILL OCCUR THROUGHOUT 2021 IN ACCORDANCE WITH TERMS OF THE SUPPLY AGREEMENT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up